Effects of puerarin on the pharmacokinetics of astragaloside IV in rats and its potential mechanism

Zhang, Huan; Song, Jiaying; Dai, Huizhen; Liu, Yanchao; Wang, Lili

doi:10.1080/13880209.2020.1746362

Cited by 8 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The improved antidiabetic activity of the combination could also have been due to pharmacokinetic interactions between the puerarin and the metformin. Puerarin is reported to inhibit CYP450 enzymes (CYP3A4, CYP2B6, and CYP2C9) and p-glycoprotein [ 56 , 57 , 58 ]; thus, it affects the pharmacokinetics of herbs and drugs [ 59 , 60 , 61 , 62 , 63 , 64 ]. However, there are no reports on the pharmacokinetic interactions between metformin and puerarin.…”

Section: Discussionmentioning

confidence: 99%

Pharmacodynamic Interactions between Puerarin and Metformin in Type-2 Diabetic Rats

Wang

et al. 2022

Molecules

View full text Add to dashboard Cite

Herb–drug interactions are vital in effectively managing type-2-diabetes complications. Puerarin is a natural isoflavonoid in the Pueraria genus, and its pharmacological activities, including antidiabetic activity, are well established. The similar modes of action of puerarin and metformin in diabetic models suggest their positive pharmacodynamic interactions. This study investigated this in streptozotocin/nicotinamide-induced type-2 diabetic rats. Puerarin at doses of 80 mg/kg, 120 mg/kg and 160 mg/kg improved the activity of metformin in reversing hyperglycaemia, dysregulated lipid profiles, dysfunction of the liver, kidney, and pancreas, and inflammation. The treatment with either puerarin (high dose, 160 mg/kg intraperitoneally) or metformin (100 mg/kg intraperitoneally) did not bring the dysregulated biomarkers to normal levels in 4 weeks. By contrast, the combination of puerarin (160 mg/kg) and metformin (100 mg/kg) did. This study is the first to report scientific evidence for the positive pharmacodynamic interactions between puerarin and metformin.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacodynamic Interactions between Puerarin and Metformin in Type-2 Diabetic Rats

Wang

et al. 2022

Molecules

View full text Add to dashboard Cite

show abstract

“…The rats in the control group received the same volume of D.W. by intragastric administration. AS-IV and D.W. were administrated 2 h before surgery ( Figure 7 ) [ 53 , 54 , 55 , 56 , 57 , 58 ].…”

Section: Methodsmentioning

confidence: 99%

Astragaloside IV Suppresses Hepatic Proliferation in Regenerating Rat Liver after 70% Partial Hepatectomy via Down-Regulation of Cell Cycle Pathway and DNA Replication

et al. 2021

View full text Add to dashboard Cite

Astragaloside IV (AS-IV) is one of the major bio-active ingredients of huang qi which is the dried root of Astragalus membranaceus (a traditional Chinese medicinal plant). The pharmacological effects of AS-IV, including anti-oxidative, anti-cancer, and anti-diabetic effects have been actively studied, however, the effects of AS-IV on liver regeneration have not yet been fully described. Thus, the aim of this study was to explore the effects of AS-IV on regenerating liver after 70% partial hepatectomy (PHx) in rats. Differentially expressed mRNAs, proliferative marker and growth factors were analyzed. AS-IV (10 mg/kg) was administrated orally 2 h before surgery. We found 20 core genes showed effects of AS-IV, many of which were involved with functions related to DNA replication during cell division. AS-IV down-regulates MAPK signaling, PI3/Akt signaling, and cell cycle pathway. Hepatocyte growth factor (HGF) and cyclin D1 expression were also decreased by AS-IV administration. Transforming growth factor β1 (TGFβ1, growth regulation signal) was slightly increased. In short, AS-IV down-regulated proliferative signals and genes related to DNA replication. In conclusion, AS-IV showed anti-proliferative activity in regenerating liver tissue after 70% PHx.

show abstract

“…Puerarin can significantly increase the plasma peak concentration of AS-IV and reduce the oral clearance rate. These characteristics suggest that puerarin can significantly change the pharmacokinetic characteristics of AS-IV by increasing the absorption of AS-IV or inhibiting its metabolism in Frontiers in Pharmacology frontiersin.org vivo (Zhang et al, 2020). Other TCM components, such as triptolide (Gao et al, 2020), cycloastragenol (He et al, 2018), atractylenolide I (Song et al, 2014), and prim-O-glucosylcimifugin (Song et al, 2014), can also change the pharmacokinetic characteristics of AS-IV.…”

Section: Pharmackinetics Of As-ivmentioning

confidence: 99%

Astragaloside IV, as a potential anticancer agent

Xia

Li²,

Tang

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer is a global intractable disease, and its morbidity and mortality are increasing year by year in developing countries. Surgery and chemotherapy are often used to treat cancer, but they result in unsatisfactory outcomes, such as severe side effects and drug resistance. With the accelerated modernization of traditional Chinese medicine (TCM), an increasing body of evidence has shown that several TCM components have significant anticancer activities. Astragaloside IV (AS-IV) is considered the main active ingredient of the dried root of Astragalus membranaceus. AS-IV exhibits various pharmacological effects, such as anti-inflammatory, hypoglycemic, antifibrotic, and anticancer activities. AS-IV possesses a wide range of activities, such as the modulation of reactive oxygen species-scavenging enzyme activities, participation in cell cycle arrest, induction of apoptosis and autophagy, and suppression of cancer cell proliferation, invasiveness, and metastasis. These effects are involved in the inhibition of different malignant tumors, such as lung, liver, breast, and gastric cancers. This article reviews the bioavailability, anticancer activity, and mechanism of AS-IV and provides suggestions for further research of this TCM.

show abstract

Effects of puerarin on the pharmacokinetics of astragaloside IV in rats and its potential mechanism

Cited by 8 publications

References 16 publications

Pharmacodynamic Interactions between Puerarin and Metformin in Type-2 Diabetic Rats

Pharmacodynamic Interactions between Puerarin and Metformin in Type-2 Diabetic Rats

Astragaloside IV Suppresses Hepatic Proliferation in Regenerating Rat Liver after 70% Partial Hepatectomy via Down-Regulation of Cell Cycle Pathway and DNA Replication

Astragaloside IV, as a potential anticancer agent

Contact Info

Product

Resources

About